DDInter686 DDInter1082
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Etacrynic acid {u} (Compound) treats {v} (Disease) hypertension
Etacrynic acid {u} (Compound) binds {v} (Gene) SLC12A1
Etacrynic acid {u} (Compound) upregulates {v} (Gene) CTSL
Etacrynic acid {u} (Compound) palliates {v} (Disease) chronic kidney failure
Etacrynic acid {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Etacrynic acid {u} (Compound) downregulates {v} (Gene) PLK1
Etacrynic acid {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Etacrynic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxytetracycline
Etacrynic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Minocycline
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pramlintide
Etacrynic acid (Compound) treats hypertension (Disease)
Etacrynic acid (Compound) binds SLC12A1 (Gene)
Etacrynic acid (Compound) upregulates CTSL (Gene)
Etacrynic acid (Compound) palliates chronic kidney failure (Disease)
Etacrynic acid (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class)
Etacrynic acid (Compound) downregulates PLK1 (Gene)
Etacrynic acid (Compound) causes Hypoglycaemia (Side Effect)
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Minocycline
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide